A new post on the Bill of Health blog discusses new research that looks at whether upper age limits should be established for population-based preventive genomic screening. These types of limits are used in other clinical screenings on the assumption that older individuals wouldn't see clinical benefits. The authors of the paper used data from the GeneScreen study to look at how age issues were perceived and valued by researchers and participants. Their findings? "While clinical benefits of preventive genomic screening for older adults are debatable, our respondents perceived a range of benefits of screening in both clinical and research settings. Researchers and clinicians should carefully consider decisions about whether to exclude older adults and whether to provide information about benefits and risks across age groups."